1. Home
  2. CGTX vs MATH Comparison

CGTX vs MATH Comparison

Compare CGTX & MATH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CGTX
  • MATH
  • Stock Information
  • Founded
  • CGTX 2007
  • MATH 2015
  • Country
  • CGTX United States
  • MATH Hong Kong
  • Employees
  • CGTX 25
  • MATH N/A
  • Industry
  • CGTX Biotechnology: Pharmaceutical Preparations
  • MATH Finance/Investors Services
  • Sector
  • CGTX Health Care
  • MATH Finance
  • Exchange
  • CGTX Nasdaq
  • MATH Nasdaq
  • Market Cap
  • CGTX 53.4M
  • MATH 60.8M
  • IPO Year
  • CGTX 2021
  • MATH N/A
  • Fundamental
  • Price
  • CGTX $0.84
  • MATH $3.35
  • Analyst Decision
  • CGTX Strong Buy
  • MATH
  • Analyst Count
  • CGTX 4
  • MATH 0
  • Target Price
  • CGTX $2.83
  • MATH N/A
  • AVG Volume (30 Days)
  • CGTX 19.4M
  • MATH 165.1K
  • Earning Date
  • CGTX 08-07-2025
  • MATH 08-26-2025
  • Dividend Yield
  • CGTX N/A
  • MATH N/A
  • EPS Growth
  • CGTX N/A
  • MATH N/A
  • EPS
  • CGTX N/A
  • MATH 0.17
  • Revenue
  • CGTX N/A
  • MATH $31,399,049.00
  • Revenue This Year
  • CGTX N/A
  • MATH N/A
  • Revenue Next Year
  • CGTX N/A
  • MATH N/A
  • P/E Ratio
  • CGTX N/A
  • MATH $21.64
  • Revenue Growth
  • CGTX N/A
  • MATH 291.58
  • 52 Week Low
  • CGTX $0.22
  • MATH $0.80
  • 52 Week High
  • CGTX $2.54
  • MATH $4.17
  • Technical
  • Relative Strength Index (RSI)
  • CGTX 72.32
  • MATH 47.87
  • Support Level
  • CGTX $0.55
  • MATH $3.25
  • Resistance Level
  • CGTX $0.87
  • MATH $3.77
  • Average True Range (ATR)
  • CGTX 0.10
  • MATH 0.37
  • MACD
  • CGTX 0.02
  • MATH -0.03
  • Stochastic Oscillator
  • CGTX 61.76
  • MATH 31.11

About CGTX Cognition Therapeutics Inc.

Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.

About MATH Metalpha Technology Holding Limited

Metalpha Technology Holding Ltd is a digital asset focused wealth management company. The company predominantly generates revenue from the execution of cryptocurrency-related transactions, which includes the issuance of derivative products to over-the-counter (OTC) clients and its proprietary trading activities. It has partnered with a crypto exchange to provide crypto derivative market-making services for its clients, facilitating the trading of crypto derivative products. In addition, the company also engages in providing traditional financial derivative products, and asset management services. It operates in a single segment which is the trading of proprietary digital assets and derivative contracts, and derives a majority of its revenue from Hong Kong.

Share on Social Networks: